BrightSpring Health Services, Inc. Stock Price, News & Analysis

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q2 2025 financial results, with net revenue reaching $3.148 billion, up 29.1% year-over-year. The company's Adjusted EBITDA grew 28.8% to $143 million, while net income from continuing operations remained flat at $8.5 million.

The company's performance was driven by significant growth in both segments: Pharmacy Solutions revenue increased 32% to $2.79 billion, while Provider Services revenue grew 11% to $358 million. Following these results, BrightSpring raised its full-year 2025 guidance, now expecting revenue between $12.2-$12.6 billion (21.1-25.1% growth) and Adjusted EBITDA of $590-$605 million (28.2-31.5% growth).

Additionally, BrightSpring's planned divestiture of its Community Living business to Sevita, announced in January 2025, is expected to complete in Q4 2025.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled its second quarter 2025 financial results announcement for August 1, 2025. The company will release its earnings before the market opens, followed by a conference call at 8:30 a.m. ET on the same day.

Interested participants can register for the conference call online. The company will also provide a live and archived webcast of the call on its investor relations website, along with related presentation materials.

BrightSpring Health Services (NASDAQ: BTSG) announced that its specialty pharmacy subsidiary Onco360® has been selected as the national pharmacy partner for multiple new cancer and rare disease treatments. The partnership covers three newly approved therapies: GOMEKLI for neurofibromatosis type 1 patients with plexiform neurofibromas, AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. This expansion strengthens Onco360's position as a leading independent specialty pharmacy in providing access, education, data, and expert support for innovative treatments targeting serious and life-threatening conditions.

BrightSpring Health Services (NASDAQ: BTSG) has announced the pricing of a secondary offering of 14 million shares of common stock at $21.75 per share by its existing stockholders, including KKR affiliates and management members. The KKR Selling Stockholder has provided underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not receive any proceeds from the offering, as all proceeds will go to the Selling Stockholders. The offering is expected to close on June 12, 2025. Goldman Sachs, BofA Securities, Jefferies, and Morgan Stanley are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. Multiple other financial institutions are participating as bookrunners and co-managers.

BrightSpring Health Services (NASDAQ: BTSG) announced a secondary offering where certain stockholders, including KKR affiliates and management members, plan to sell 14 million shares of common stock. The KKR Selling Stockholder will grant underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not sell any shares or receive proceeds from this offering. Goldman Sachs and BofA Securities are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. The offering will be made through a shelf registration statement filed with the SEC on June 10, 2025.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q1 2025 financial results and raised its full-year guidance. The company achieved Q1 net revenue of $2.878 billion, up 25.9% year-over-year, and turned around from a loss to net income of $9.2 million. Adjusted EBITDA grew 28.2% to $131 million. The Pharmacy Solutions segment led growth with revenue up 28% to $2.532 billion, while Provider Services revenue increased 12% to $346 million. BrightSpring increased its 2025 guidance, now expecting revenue of $12-12.5 billion (19.1-24.1% growth) and adjusted EBITDA of $570-585 million (23.9-27.2% growth). The company's planned divestiture of its Community Living business to Sevita remains on track for completion this year.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled the release of its first quarter 2025 financial results for Friday, May 2, 2025. The announcement will be made before the company's earnings conference call, which is set for 8:30 a.m. ET on the same day.

Interested participants can register for the conference call prior to the 8:30 a.m. ET start time. The company will make both a live and archived webcast available on their investor relations website at ir.brightspringhealth.com under the 'Events & Presentations' section, where related presentation materials will also be posted before the call.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q4 and full year 2024 results, with significant revenue growth and improved profitability. Q4 net revenue increased 28.6% to $3,053 million, with net income of $15.4 million compared to a loss in Q4 2023. Full year revenue grew 27.6% to $11,266 million, while net loss improved to $20.5 million from $156.8 million in 2023.

The company announced plans to divest its Community Living business to Sevita for $835 million. For 2025, BrightSpring increased guidance (excluding Community Living), projecting revenue of $11,600-$12,100 million (15.2-20.1% growth) and Adjusted EBITDA of $545-560 million (18.4-21.7% growth). The Pharmacy Segment is expected to grow 15.9-21.1%, while the Provider Segment is forecast to grow 10.0-13.8%.

BrightSpring Health Services (NASDAQ: BTSG) has announced the promotion of Jennifer Phipps to Chief Financial Officer, effective March 4, 2025, succeeding Jim Mattingly. Phipps, who brings over 20 years of healthcare financial experience, has served at BrightSpring for eight years in multiple roles including Chief Accounting Officer and CFO of the Home Health and Hospice segment.

During her tenure at BrightSpring, Phipps has led technology implementations to streamline financial processes, built a lean-focused procurement team, and implemented various accounting systems. She played a important role in the company's IPO and has maintained active involvement in public company processes. Prior to BrightSpring, she held leadership positions at Cardinal Health and spent six years at Ernst & Young.

Phipps holds a CPA license and received her Bachelor's and Master's in Accounting from The Ohio State University. She will lead BrightSpring's financial operations, supporting the company's mission of providing community-based pharmacy and provider health solutions to complex populations.